Patents by Inventor Kyriacos A. Mitrophanous

Kyriacos A. Mitrophanous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050042234
    Abstract: Provided herein are methods for producing a replication defective retrovirus, which comprises transfecting a producer cell with (1) a retroviral genome; (2) a nucleotide sequence coding for retroviral gag and pol proteins that is codon-optimized for expression in the producer cell; and (3) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (1).
    Type: Application
    Filed: April 18, 2001
    Publication date: February 24, 2005
    Inventors: Alan Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos Mitrophanous
  • Patent number: 6818209
    Abstract: A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by the retroviral delivery system; wherein the first nucleotide sequence is heterologous with respect to at least one of the other nucleotide sequences; and wherein the first nucleotide sequence codes for at least a part of a rabies G protein or a mutant, variant, derivative or fragment thereof that is capable or recognising the target site.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: November 16, 2004
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Kyriacos A. Mitrophanous, Deva Patil, Alan J. Kingsman, Susan M. Kingsman, Fiona M. Ellard
  • Patent number: 6783981
    Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles, (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product; wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: August 31, 2004
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Mark Uden, Kyriacos Mitrophanous
  • Publication number: 20040086488
    Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.
    Type: Application
    Filed: September 11, 2003
    Publication date: May 6, 2004
    Inventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous
  • Publication number: 20040040052
    Abstract: A method of producing a transgenic cell comprising introducing into a cell a non-primate lentiviral expression vector comprising a nucleotide of interest (NOI). Also described is a method of producing a transgenic cell comprising introducing into a cell a lentiviral expression vector comprising a NOI capable of generating an antisense oligonucleotide, a ribozyme, an siRNA, a short hairpin RNA, a micro-RNA or a group 1 intron. Also described is a viral vector comprising a first nucleotide sequence, wherein said first nucleotide sequence comprises: (a) a second nucleotide sequence comprising an aptazyme; and (b) a third nucleotide sequence capable of generating a polynucleotide; wherein (a) and (b) are operably linked and wherein the aptazyme is activatable to cleave a transcript of the first nucleotide sequence such that said polynucleotide is generated.
    Type: Application
    Filed: April 24, 2003
    Publication date: February 26, 2004
    Applicant: Oxford BioMedica (UK) Limited
    Inventors: Philippa Radcliffe, Kyriacos Mitrophanous, Michael Themis
  • Publication number: 20040009603
    Abstract: A viral vector production system is provided which system comprises:
    Type: Application
    Filed: January 27, 2003
    Publication date: January 15, 2004
    Inventors: Alan John Kingsman, Kyriacos Mitrophanous, Narry Kim
  • Patent number: 6669936
    Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: December 30, 2003
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous
  • Publication number: 20030147907
    Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.
    Type: Application
    Filed: May 29, 2001
    Publication date: August 7, 2003
    Inventors: Alan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim
  • Publication number: 20030143205
    Abstract: An alpha-lentivirus vector comprising at least one alphaviral component and at least one lentiviral component, wherein the lentiviral component is capable of being packaged into a lentiviral particle after introduction of said vector into a human cell.
    Type: Application
    Filed: July 22, 2002
    Publication date: July 31, 2003
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: Jason Slingsby, Kyriacos Mitrophanous, Jonathan Rohll, Alison Lawrie
  • Publication number: 20030121062
    Abstract: A method of producing a transgenic cell comprising introducing into a cell a non-primate lentiviral expression vector comprising a nucleotide of interest (NOI).
    Type: Application
    Filed: February 26, 2002
    Publication date: June 26, 2003
    Applicant: Oxford BioMedica (UK) Limited
    Inventors: Philippa Radcliffe, Kyriacos Mitrophanous, Michael Themis
  • Patent number: 6541248
    Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product. The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: April 1, 2003
    Assignee: Oxford BioMedica Limited
    Inventors: Alan John Kingsman, Kyriacos Mitrophanous, Narry Kim
  • Publication number: 20020034502
    Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.
    Type: Application
    Filed: July 25, 2001
    Publication date: March 21, 2002
    Inventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous
  • Publication number: 20020034393
    Abstract: A retroviral vector capable of delivering an NOI and comprising an exogenous second synthesis element.
    Type: Application
    Filed: May 18, 2001
    Publication date: March 21, 2002
    Inventors: Kyriacos A. Mitrophanous, Mark Uden, Jonathan Rohll, Susan Mary Kingsman, Alan John Kingsman
  • Patent number: 6312683
    Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: November 6, 2001
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Alan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim
  • Patent number: 6312682
    Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: November 6, 2001
    Assignee: Oxford BioMedica plc
    Inventors: Alan John Kingsman, Susan Mary Kingsman, Narry Kim, Kyriacos Mitrophanous